TARA SANDS: Open Payments
NPI 1992035778 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$647 in 31 payments from 10 companies in 2025. Trend: 2023 $686 · 2024 $1,106 · 2025 $647
Food & beverage: $647
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 4 | $174 |
| ABBVIE INC. | 9 | $145 |
| Biosense Webster, Inc. | 5 | $109 |
| PFIZER INC. | 3 | $55 |
| Otsuka America Pharmaceutical, Inc. | 3 | $48 |
| Lilly USA, LLC | 2 | $33 |
| Exact Sciences Corporation | 2 | $30 |
| Gilead Sciences, Inc. | 1 | $21 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $17 |
| AstraZeneca Pharmaceuticals LP | 1 | $15 |
Products named: CARTO 3, UBRELVY, ELIQUIS, REXULTI, QULIPTA, MOUNJARO, Ozempic, Cologuard Collection Kit.
Industry payments across NE — which companies pay providers there.
